MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Automatic and objective speech analysis in Huntington disease

J. Adams, E. Dorsey, M. Coffey, M. Pawlik, C. Tarolli, R. Schneider, B. Najafi, H. Zhou, A. Vaziri, H. Nguyen (Rochester, USA)

Meeting: MDS Virtual Congress 2021

Abstract Number: 221

Keywords: Dysarthria

Category: Huntington's Disease

Objective: To investigate the use of digital technology to assess speech in people with Huntington disease (HD).

Background: Dysarthria is common in Huntington disease and changes in speech may be detected before the manifest of overt motor symptoms (1,2). Thus, there is potential for using speech biomarkers as an objective indicator of HD symptom onset, which may be useful in disease-modifying therapies and clinical trials targeting individuals with premanifest and early manifest HD.

Method: 53 participants were included in the analysis (mean age=43.3±13.2 years). 9 participants were classified as prodromal-HD, 22 as manifest HD (UHDRS score=42.0±15.1), and 22 controls. Participants were asked to perform three speech assessment tests at their natural pace and voice: reading of the Rainbow Passage, counting from 1 to 50, and counting backwards from 50 by 3. Data were obtained using a voice recorder with a microphone clipped to the participant collar. Data were sampled at 44.1 kHz. Dysarthria was assessed as part of the UHDRS (average dysarthria score of HD (1.32±0.65), prodromal-HD (0.02±0.15), controls (0.0±0.0)). Acoustic and clinical metrics such as pitch, pitch variation, loudness, loudness variation, and power were extracted for analysis. Univariate analysis was used to compare across groups while adjusting for age, sex and education level. Significance was set at alpha=0.05 and Cohen’s coefficient (d) was used to measure effect size.

Results: Participants with HD exhibited significantly lower pitch and pitch variation, loudness, speech rate and backwards counting rate, but higher loudness variation and counting error than prodromal-HD patients (d ranges from 0.53-1.57) and controls (d=0.15-2.09), while the largest effect was observed in loudness variation (41% increase, p<0.001, d=1.57 and 58% increase, p<0.001, d=2.09, respectively). Prodromal-HD participants exhibited significantly lower power than controls (p=0.011, d=0.93). The extracted features were able to distinguish between groups with different UHDRS dysarthria scores of 0 (n=32), 1 (n=14), and ≥2 (n=7) (p<0.050, d=0.93-2.85).

Conclusion: Digital technology can automatically assess speech performance in people with HD and can differentiate based on disease status and UHDRS dysarthria score. Development of objective and sensitive metrics to assess speech changes early in disease could be beneficial for novel therapies and clinical trials.

References: [1] Vogel et al. Speech acoustic markers of early stage and prodromal Huntington’s disease: a marker of disease onset? Neuropsychologia 2012;50:3273–3278. [2] Harrington et al. Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2012;83:612–619.

To cite this abstract in AMA style:

J. Adams, E. Dorsey, M. Coffey, M. Pawlik, C. Tarolli, R. Schneider, B. Najafi, H. Zhou, A. Vaziri, H. Nguyen. Automatic and objective speech analysis in Huntington disease [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/automatic-and-objective-speech-analysis-in-huntington-disease/. Accessed May 13, 2025.
  • Tweet
  • Email
  • Print

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/automatic-and-objective-speech-analysis-in-huntington-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley